Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2013

View Archived Issues

Consortium developing placental malaria vaccine receives E.U. grant

Dr. Reddy's Laboratories presents new series of CETP inhibitors

Glenmark Pharmaceuticals presents new ITK/TSK inhibitors

Alzheimer's Drug Discovery Foundation awards grant for novel peptide research

HUYA Bioscience enters collaboration with Zhangjiang Biotech Pharmaceutical Base

Senesco takes steps to accelerate enrollment in phase Ib/IIa study of anticancer candidate

SynapDx and Illumina join to develop early detection tools for autism

Galapagos achieves milestones in Servier alliances

Pfizer presents promising phase IIa results for topical tofacitinib in plaque psoriasis

Phase II study of palifosfamide in incurable germ cell tumors begins

First patient enrolled in third phase III study of laquinimod in multiple sclerosis

Novogen signs memorandum of understanding with The Ingham Institute

VAC-3S immunotherapeutic proves safe and well tolerated in HIV-1

Cylene and TetraGene enter exclusive worldwide agreement for anticancer candidate

Genentech presents phase I results for GDC-0068

Second Sight's Argus II Retinal Prosthesis implanted in first patients in the Middle East

KM-023 demonstrates good tolerance and pharmacokinetics in a phase I trial

Athera Biotechnologies and Dyax patent novel antibodies

Gervais Danone discloses new bacterial strains for infections

Researchers at Two to Biotech divulge new peptides

Maximum tolerated dose defined in CH-5132799 study

Japanese launch of Cimzia for rheumatoid arthritis

GSK files for European approval of albiglutide

Janssen files MAA for fixed-dose combination of canagliflozin and metformin

DSP and Nippon Shinyaku sign Japanese agreement for SMP-986

U.K. approval for Duexis for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...